Adamas Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ADAMAS PHARMA, and when can generic versions of ADAMAS PHARMA drugs launch?
ADAMAS PHARMA has two approved drugs.
There are twenty-eight US patents protecting ADAMAS PHARMA drugs.
There are forty-two patent family members on ADAMAS PHARMA drugs in eleven countries.
Summary for Adamas Pharma
International Patents: | 42 |
US Patents: | 28 |
Tradenames: | 2 |
Ingredients: | 1 |
NDAs: | 2 |
Patent Litigation for Adamas Pharma: | See patent lawsuits for Adamas Pharma |
PTAB Cases with Adamas Pharma as patent owner: | See PTAB cases with Adamas Pharma as patent owner |
Drugs and US Patents for Adamas Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 8,895,617 | See Plans and Pricing | See Plans and Pricing | ||||
Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | 8,895,614 | See Plans and Pricing | Y | See Plans and Pricing | |||
Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-002 | Aug 24, 2017 | RX | Yes | Yes | 8,895,616 | See Plans and Pricing | See Plans and Pricing | ||||
Adamas Pharma | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | RX | Yes | No | 9,867,791 | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Adamas Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
Adamas Pharma | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RE39069 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Adamas Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2782556 | See Plans and Pricing |
Brazil | 112020003375 | See Plans and Pricing |
Australia | 2010325960 | See Plans and Pricing |
Canada | 2588296 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.